Safety and efficacy comparison of gel and emulgel formulations of Tertinoin and Clindamaycin for treatment of mild to moderate acne vulgaris
Phase 2
Recruiting
- Conditions
- Acne vulgaris.Acne vulgarisL70.0
- Registration Number
- IRCT20150101020514N13
- Lead Sponsor
- Jarf Andishan Nnavid Salamat knowlage based company (JANUS)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Male or female aged 16-40 years
Mild to moderate inflammatory or non-inflammatory acne lesions (grade 1 to 3 according to the table) on face
Exclusion Criteria
People with allergies to formulation ingredients
Nodular or cystic lesions that represent a severe type of acne vulgaris
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluate the improvement of acne severity index by a physician. Timepoint: Before intervention, 4 and 8 weeks after the start of use. Method of measurement: An independent dermatologists perform evaluation and scoring with the help of photos based on the percentage of improvement in acne using:(0=normal skin, 2=skin is almost clear, 3=some non-inflammatory lesions are present, 4=non-inflammatory lesions are predominant, with multiple inflammatory lesions. 5=highly inflammatory lesions predominate).
- Secondary Outcome Measures
Name Time Method Trans Epidermal Water Loss. Timepoint: Before intervention, 4 and 8 weeks after the start of use. Method of measurement: Tewameter.;Skin sebum. Timepoint: Before intervention, 4 and 8 weeks after the start of use. Method of measurement: Sebumeter.